274 / 1498
Cardiovascular disease after therapy for HL:
A detailed analysis of 9 collaborative EORTC-LYSA trials
Maraldo et al, Lancet Hemat in press
Cumulative incidence curves of first cardiovascular disease by LSQ-responder status and for the
whole cohort (n=6,039)
LSQ responder
LSQ non responder
Total cohort